Inclusion Criteria:

          1. Documented informed consent of the participant and/or legally authorized
             representative.

          2. Agreement to allow the use of archival tissue from diagnostic tumor biopsies.

          3. If unavailable, exceptions may be granted with study PI approval.

          4. Age ≥ 18 years.

          5. ECOG ≤ 2.

          6. Life expectancy ≥ 16 weeks.

          7. Histologically confirmed B-ALL or B-cell lymphoblastic lymphoma

          8. Relapsed/refractory disease after failure of ≥ 2 prior lines of therapy.

          9. Evidence of active BAFF-R expression at the time of enrollment.

         10. Recovered to ≤ Grade 1 from the acute toxic effects (except alopecia) of prior
             anti-cancer therapy.

         11. No known contraindications to leukapheresis, steroids or tocilizumab.

         12. Ineligible for or failed prior CD19-targeted immunotherapy (e.g., blinatumomab or
             CD19-CAR T cells).

         13. For participants to be eligible for the trial following prior CD19-CAR T cell therapy
             at least 90-days has elapsed since participant received last CD19-CAR T cell therapy.

         14. Participants with CNS involvement by leukemia (CNS2 and asymptomatic CNS3) may be
             considered eligible after discussions with the study team.

         15. Total serum bilirubin ≤2.0 mg/dL (unless has Gilbert's disease or leukemia involvement
             of the liver, then ≤3.0)

         16. AST ≤2.5 x ULN

         17. ALT ≤ 2.5 x ULN

         18. Creatinine clearance of ≥ 50 mL/min per 24-hour urine test or the Cockcroft-Gault
             formula

         19. Left ventricular ejection fraction (LVEF) ≥ 50%

         20. O2 saturation ≥ 92% on room air.

         21. Seronegative for HIV Ag/Ab combo, HCV*, and active HBV (Surface Antigen Negative)

         22. *If positive, Hepatitis C RNA quantitation must be performed and must be undetectable.

         23. Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the
             urine test is positive or cannot be confirmed as negative, a serum pregnancy test will
             be required

         24. Agreement by females and males of childbearing potential^ to use an effective method
             of birth control or abstain from heterosexual activity for the course of the study
             through at least 3 months after the last dose of protocol therapy.

               -  Childbearing potential defined as not being surgically sterilized (men and women)
                  or have not been free from menses for > 1 year (women only).

        Exclusion Criteria:

          1. Autologous/allogeneic stem cell transplant within 100 days at the time of enrollment.

          2. Concurrent use of systemic steroids or chronic use of immunosuppressant medications.
             Recent or current use of inhaled steroids is not exclusionary. Physiologic replacement
             of steroids (prednisone ≤ 7.5 mg /day or equivalent) is allowed

          3. Auto-immune disease or active GVHD requiring systemic immunosuppressant therapy.

          4. Class III/IV cardiovascular disability according to the New York Heart Association
             (NYHA) Classification.

          5. Subjects with clinically significant arrhythmia or arrhythmias not stable on medical
             management within 2 weeks of enrollment.

          6. Subjects with a known history or prior diagnosis of optic neuritis or other
             immunologic or inflammatory disease affecting the central nervous system, including
             seizure disorder.

          7. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to study agent.

          8. Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia.

          9. History of stroke or intracranial hemorrhage within 6 months of enrollment.

         10. History of other malignancies, except for malignancy surgically resected (or treated
             with other modalities) with curative intent, basal cell carcinoma of the skin or
             localized squamous cell carcinoma of the skin; non-muscle invasive bladder cancer;
             malignancy treated with curative intent with no known active disease present for ≥ 3
             years.

         11. Clinically significant uncontrolled illness.

         12. Active systemic uncontrolled infection requiring antibiotics.

         13. Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection.

         14. Females only: Pregnant or breastfeeding.

         15. Any other condition that would, in the investigator's judgment, contraindicate the
             subject's participation in the clinical study due to safety concerns with clinical
             study procedures.

         16. Prospective participants who, in the opinion of the investigator, may not be able to
             comply with all study procedures (including compliance issues related to
             feasibility/logistics).